AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

argenx SE

Regulatory Filings Nov 10, 2021

6221_iss_2021-11-10_8473d407-4924-44bb-8263-e4c523a935cb.pdf

Regulatory Filings

Open in Viewer

Opens in native device viewer

argenx to Present at Upcoming Investor Conferences

November 10, 2021

Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in several upcoming conferences:

  • Guggenheim Healthcare Talks | Idea Forum | 3rd Annual Neuro/Immunology Day. Fireside chat on Monday, November 15, 2021 at 9:40 a.m. ET.
  • Evercore ISI 4th Annual HealthCONx Conference. Fireside chat on Tuesday, November 30, 2021 at 12:35 p.m. ET.
  • Piper Sandler 33rd Annual Healthcare Conference. Pre-recorded fireside chat will be made available on November 22, 2021 at 10:00 a.m. ET.

Additional information regarding these events will be available on the Investors section of the argenx website at argenx.com/investors.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland. For more information, visit www.argenx.com and follow us on LinkedIn and Twitter.

For further information, please contact:

Media: Kelsey Kirk [email protected]

Joke Comijn (EU) [email protected]

Investors:

Beth DelGiacco [email protected]

Michelle Greenblatt [email protected]

Talk to a Data Expert

Have a question? We'll get back to you promptly.